Harumi Yamada

Harumi Yamada

Auto-generated profile, based on publicly available information

Harumi Yamada

Department of Epigenomics, Institute for Advanced Life Sciences, Hoshi University, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2025 in Gut
Verified
Journal Article
Open access
PDF file
HYHarumi Yamada
Harumi Yamada
SASeiirhicro Abe
Seiirhicro Abe
HCHadrien Charvat
Hadrien Charvat
TATakayuki Ando
Takayuki Ando
MMMasahiro Maeda
Masahiro Maeda
TUToshikazu Ushijima
Toshikazu Ushijima
Background: Precision cancer risk stratification for gastric cancer is urgently needed for the growing number of healthy people after Helicobacter pylori eradication. The epimutation burden in non-malignant tissues has been associated with cancer risk in multiple cross-sectional studies. Objective: To confirm the clinical usefulness of a DNA methylation marker for epimutation burden, and to identify a cut-off methylation level for a super-high-risk population. Design: Healthy people after H. pylori eradication with open-type atrophy were prospectively recruited. DNA methylation levels of a marker gene, RIMS1 , were measured in biopsy specimens from gastric antrum and body. The primary endpoint was the incidence rate of gastric cancer in quartiles of the methylation levels. Results: 1624 participants had at least one endoscopic follow-up with a median follow-up of 4.05 years, and a primary gastric cancer developed in 27 participants. The highest quartile of RIMS1 methylation levels had a higher incidence rate (972.8 per 100 000 person-years) than the lowest quartile (127.1). Cox regression analysis revealed a univariate HR of 7.7 (95% CI 1.8–33.7) and an age- and sex-adjusted HR of 5.7 (95% CI 1.3–25.5). As a secondary objective, a cut-off methylation level of 25.7% (95% CI 1.7–7.7) was obtained to identify a population with a super-high risk based on the number needed to screen of 1000. Conclusion: A DNA methylation marker can risk-stratify healthy people after H. pylori eradication even though all of them have clinically high risk. Individuals with super-high risk will need more frequent gastric cancer screening than currently recommended. Trial registration number: UMIN-CTR000016894.

5 February 2022 in Cancer Letters
Verified
Journal Article
Closed access
HYHarumi Yamada
Harumi Yamada
HTHideyuki Takeshima
Hideyuki Takeshima
RFRyoji Fujiki
Ryoji Fujiki
SYSatoshi Yamashita
Satoshi Yamashita
SSShigeki Sekine
Shigeki Sekine
TUToshikazu Ushijima
Toshikazu Ushijima

27 July 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SUSho Ueda
Sho Ueda
SYSatoshi Yamashita
Satoshi Yamashita
MNMiho Nakajima
Miho Nakajima
TKTadashi Kumamoto
Tadashi Kumamoto
COChitose Ogawa
Chitose Ogawa
TUToshikazu Ushijima
Toshikazu Ushijima
Somatic mutations are accumulated in normal human tissues with aging and exposure to carcinogens. If we can accurately count any passenger mutations in any single DNA molecule, since their quantity is much larger than driver mutations, we can sensitively detect mutation accumulation in polyclonal normal tissues. Duplex sequencing, which tags both DNA strands in one DNA molecule, enables accurate count of such mutations, but requires a very large number of sequencing reads for each single sample of human-genome size. Here, we reduced the genome size to 1/90 using the Bam HI restriction enzyme and established a cost-effective pipeline. The enzymatically cleaved and optimal sequencing (EcoSeq) method was able to count somatic mutations in a single DNA molecule with a sensitivity of as low as 3 × 10 −8 per base pair (bp), as assessed by measuring artificially prepared mutations. Taking advantages of EcoSeq, we analyzed normal peripheral blood cells of pediatric sarcoma patients who received chemotherapy ( n = 10) and those who did not ( n = 10). The former had a mutation frequency of 31.2 ± 13.4 × 10 −8 per base pair while the latter had 9.0 ± 4.5 × 10 −8 per base pair ( P < 0.001). The increase in mutation frequency was confirmed by analysis of the same patients before and after chemotherapy, and increased mutation frequencies persisted 46 to 64 mo after chemotherapy, indicating that the mutation accumulation constitutes a risk of secondary leukemia. EcoSeq has the potential to reveal accumulation of somatic mutations and exposure to environmental factors in any DNA samples and will contribute to cancer risk estimation.

1 December 2004 in Ozone: Science & Engineering
Verified
Journal Article
Closed access
TMTadao Mizuno
Tadao Mizuno
HYHarumi Yamada
Harumi Yamada
HTHiroshi Tsuno
Hiroshi Tsuno
The contribution of ozone and hydroxyl radical to the formation of bromate ion was investigated in a continuous flow reactor. Experiments were conducted under a wide range of ozone dose (0.7 ∼ 3.8 mgL), pH (6.5 ∼ 8.5), and t-butanol concentration (0 ∼ 0.5 mM). The formation of bromate ion was found to depend on radical reaction pathway, because the amount of bromate ion formed increased with pH and decreased with t-butanol, a radical scavenger, even when dissolved ozone concentrations were almost the same. In fact, the amount of bromate ion formed was reduced by 90% in the presence of t-butanol. Furthermore, the formation of bromate ion occurred even when dissolved ozone was not significantly detected in the presence of organic matter (TOC of 1 mgCL). The second-order reaction rate constant of hydroxyl radical with bromide ion, k HO,Br− of 1.7 × 109 (M−1s−1), was obtained on the assumption that the reactions of bromide ion and t-butanol with hydroxyl radical were competitive with each other in the presence of t-butanol and that the formation of bromate ion depended on the reaction of bromide ion with hydroxyl radical. Therefore, it is concluded that the reaction of bromide ion with hydroxyl radical dominated in the overall reaction from bromide ion to bromate ion in the continuous flow reactor.